Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: Results from the International Migraine Pain Assessment Clinical Trial (IMPACT)

• Published in: Cephalalgia 2010-11, Vol.30 (11), p.1336-1345
• Main Authors: Lipton, Richard B, Grosberg, Brian, Singer, Richard P, Pearlman, Starr H, Sorrentino, James V, Quiring, John N, Saper, Joel R
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Diclofenac - administration & dosage; Diclofenac - adverse effects; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders - drug therapy; Powders; Treatment Outcome; Young Adult
• ISSN: 0333-1024; 1468-2982
• DOI: 10.1177/0333102410367523

Objective: This study assessed the efficacy of diclofenac potassium for oral solution, a novel water-soluble buffered powder formulation, versus placebo for the acute treatment of migraine. Diclofenac potassium for oral solution has a time to maximum plasma concentration (Tmax) of 15 minutes, suggesting the potential for a rapid onset of therapeutic effects. Methods: This was a randomized, double-blind, parallel-group, placebo-controlled study conducted in 23 US centers. Adult sufferers with an established migraine diagnosis according to the International Classification of Headache Disorders, second edition (ICHD-II), treated one moderate or severe attack with 50 mg diclofenac potassium for oral solution (dissolved in approximately 2 ounces of water; N = 343) or matching placebo (N = 347). Four co-primary endpoints included the percentage of subjects who at two hours post-treatment reported no headache pain, no nausea, no photophobia and/or no phonophobia. Results: Significantly more subjects treated with diclofenac potassium for oral solution (N = 343) achieved a two-hour pain-free response (25% vs. 10%, p